Across TCGA pan-cancer cohorts, ATP1A1 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ATP1A1 data layer compared with 21 for mass-spec protein and 3 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ATP1A1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP1A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
HNSC, UCEC, and BLCA are the cancer types where ATP1A1 Mutation most reproducibly stratifies survival.